An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum: In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices lead to overdiagnosis and overtreatment, necessitating more effective tools for discriminating between aggressive and non-aggressive disease. The EU-funded ProCAncer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment. To achieve this, partners will generate a large interoperable repository of health images, and a scalable high-performance computing platform hosting the largest collection of PC Magnetic Resonance Images used for developing robust PC AI models. To ensure the rapid clinical implementation of the models developed, the project’s partners will robustly monitor performance, accuracy and reproducibility.
ProCAncer-I
An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Category: European
Funding Agency: European Commission
Programme: H2020-SC1-FA-DTS-2019-1
Programme Nature: AI for Health Imaging
Coordinator: FORTH-ICS
Start Date: 01.10.2020
Expiration Date: 30.09.2024
Duration: 48 months
Total Budget: 9997870,00€
FORTH ICS Budget: 1372187,50€
Related URL: https://www.procancer-i.eu/
Partners: FUNDACAO D.ANNA SOMMER CHAMPALIMAUD E DR. CARLOSS MONTEZ CHAMPALIMAUD, RADBOUDUMC, FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA, UNIVERSITY OF PISA, INSTITUT PAOLI CALMETTES, HACETTEPE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF RADIOLOGY, FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA DOCTOR JOSEP TRUETA, JCC DIAGNOSTIC IMAGING, NATIONAL CANCER INSTITUTE, GENERAL ANTI -CANCER AND ONCOLOGICAL HOSPITAL OF ATHENS, "ST.SAVVAS" , ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST, QS INSTITUTO DE INVESTIGATION E INNOVACION SL , CANDIOLO CANCER INSTITUTE, FRO -IRCCS , CONSIGLIO NAZIONALE DELLE RICERCHE, MASSACHUSETTS GENERAL HOSPITAL (THE GENERAL HOSPITAL CORP), BIOTRONICS 3D LIMITED, ADVANTIS MEDICAL IMAGING SINGLE MEMBER PC, QUIBIM, SOCIEDAD LIMITADA, UNIVERSITY OF VIENNA
Funding Agency: European Commission
Programme: H2020-SC1-FA-DTS-2019-1
Programme Nature: AI for Health Imaging
Coordinator: FORTH-ICS
Start Date: 01.10.2020
Expiration Date: 30.09.2024
Duration: 48 months
Total Budget: 9997870,00€
FORTH ICS Budget: 1372187,50€
Related URL: https://www.procancer-i.eu/
Partners: FUNDACAO D.ANNA SOMMER CHAMPALIMAUD E DR. CARLOSS MONTEZ CHAMPALIMAUD, RADBOUDUMC, FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA, UNIVERSITY OF PISA, INSTITUT PAOLI CALMETTES, HACETTEPE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF RADIOLOGY, FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA DOCTOR JOSEP TRUETA, JCC DIAGNOSTIC IMAGING, NATIONAL CANCER INSTITUTE, GENERAL ANTI -CANCER AND ONCOLOGICAL HOSPITAL OF ATHENS, "ST.SAVVAS" , ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST, QS INSTITUTO DE INVESTIGATION E INNOVACION SL , CANDIOLO CANCER INSTITUTE, FRO -IRCCS , CONSIGLIO NAZIONALE DELLE RICERCHE, MASSACHUSETTS GENERAL HOSPITAL (THE GENERAL HOSPITAL CORP), BIOTRONICS 3D LIMITED, ADVANTIS MEDICAL IMAGING SINGLE MEMBER PC, QUIBIM, SOCIEDAD LIMITADA, UNIVERSITY OF VIENNA
Description:
Objectives:
The vision of the ProCAncer-I is to be realized by a set of specific, interrelated, ambitious, yet totally realistic, objectives.
- Develop a comprehensive data resource related to prostate cancer for clinical care, research and innovation.
- Design, develop and deploy the (security, interoperability, transparency, sharing) for a medical imaging repository and cloud-based platform compliant to necessary standards trustworthy AI analytics workflows
- Develop and deploy novel AI models to address the unanswered clinical questions regarding prostate cancer management across the disease continuum.
- Create a sustainable infrastructure for future use and develop novel sustainability models
- Validate, verify and explain or interpret the performance of AI models in order to increase trust and render them applicable in clinical practice.
- Advance clinical knowledge and patient care in the second most common form of cancer
- Addressing a significant societal problem in the second most common form of cancer ( Prostate Cancer) by supporting efficient disease management across the care continuum
Contact person(s): Prof. Manolis Tsiknakis